Canada’s baby boomers are edging into their retirement years, marking a great demographic shift. Add to that the fact that we’re living longer than ever (the number of centenarians is set to triple, to more than 14,000 people, by 2031) and Canadians are having fewer babies, and it’s clear that Canada’s aging population is growing — and it’s a growing concern.
Read more »
Volume 5, Number 2
“An integral part of the Canadian argument should involve engagement with the North,” says Martin Grant, dean of the Faculty of Science. Here, some of McGill’s polar researchers, from across several faculties, weigh in on this most Canadian — and increasingly topical — subject.
Volume 5, Number 1
When it comes to many things—politics, currency, language, culture—borders can be much more than hypothetical demarcations. But as far as something like a virus is concerned, the division between countries A and B is just meaningless lines on a map.
Read The Article »
Volume 4, Number 1
In the world of McGill research, creating new knowledge isn’t an end—it’s the beginning of life-changing innovations.
Volume 4, Number 1
Researchers aspire to serve the greater good. Ironically, the instinct to publish and disclose, while well-intentioned, may be counterproductive.
Volume 4, Number 1
The International Expert Group on Biotechnology, Innovation and Intellectual Property, led by McGill law professor Richard Gold, argues that a new intellectual property era may be nigh.
Volume 4, Number 1
Communicating market dynamics to researchers is just one function of university commercialization units. Its main function is translating a discovery into a marketable product or service. And that’s not always easy.
Volume 4, Number 1
When a technology is too far along to receive funding from “research” sources (such as government funding agencies), yet not developed enough to attract investors or partnership/licensing arrangements with large companies, it’s said to be languishing in the limbo known as the “Valley of Death.”
Volume 4, Number 1
History teaches us that major medical breakthroughs can languish for generations or even disappear completely if they don’t bridge the gap between research and commercial application.
